JP2023058612A5 - - Google Patents

Download PDF

Info

Publication number
JP2023058612A5
JP2023058612A5 JP2023017898A JP2023017898A JP2023058612A5 JP 2023058612 A5 JP2023058612 A5 JP 2023058612A5 JP 2023017898 A JP2023017898 A JP 2023017898A JP 2023017898 A JP2023017898 A JP 2023017898A JP 2023058612 A5 JP2023058612 A5 JP 2023058612A5
Authority
JP
Japan
Prior art keywords
metabolite
acid
subject
biomarkers
acid amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023017898A
Other languages
English (en)
Japanese (ja)
Other versions
JP7451791B2 (ja
JP2023058612A (ja
Filing date
Publication date
Priority claimed from JP2019514825A external-priority patent/JP7225090B2/ja
Application filed filed Critical
Publication of JP2023058612A publication Critical patent/JP2023058612A/ja
Publication of JP2023058612A5 publication Critical patent/JP2023058612A5/ja
Priority to JP2024034012A priority Critical patent/JP7692508B2/ja
Application granted granted Critical
Publication of JP7451791B2 publication Critical patent/JP7451791B2/ja
Priority to JP2025092519A priority patent/JP2025124816A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023017898A 2016-09-16 2023-02-08 接触活性化系に関連する疾患の代謝物バイオマーカー Active JP7451791B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024034012A JP7692508B2 (ja) 2016-09-16 2024-03-06 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2025092519A JP2025124816A (ja) 2016-09-16 2025-06-03 接触活性化系に関連する疾患の代謝物バイオマーカー

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662395770P 2016-09-16 2016-09-16
US62/395,770 2016-09-16
US201762518367P 2017-06-12 2017-06-12
US62/518,367 2017-06-12
JP2019514825A JP7225090B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患の代謝物バイオマーカー
PCT/US2017/051755 WO2018053247A1 (en) 2016-09-16 2017-09-15 Metabolite biomarkers for diseases associated with the contact activation system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019514825A Division JP7225090B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患の代謝物バイオマーカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034012A Division JP7692508B2 (ja) 2016-09-16 2024-03-06 接触活性化系に関連する疾患の代謝物バイオマーカー

Publications (3)

Publication Number Publication Date
JP2023058612A JP2023058612A (ja) 2023-04-25
JP2023058612A5 true JP2023058612A5 (https=) 2023-10-10
JP7451791B2 JP7451791B2 (ja) 2024-03-18

Family

ID=59974882

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019514825A Active JP7225090B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2023017898A Active JP7451791B2 (ja) 2016-09-16 2023-02-08 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2024034012A Active JP7692508B2 (ja) 2016-09-16 2024-03-06 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2025092519A Pending JP2025124816A (ja) 2016-09-16 2025-06-03 接触活性化系に関連する疾患の代謝物バイオマーカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019514825A Active JP7225090B2 (ja) 2016-09-16 2017-09-15 接触活性化系に関連する疾患の代謝物バイオマーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024034012A Active JP7692508B2 (ja) 2016-09-16 2024-03-06 接触活性化系に関連する疾患の代謝物バイオマーカー
JP2025092519A Pending JP2025124816A (ja) 2016-09-16 2025-06-03 接触活性化系に関連する疾患の代謝物バイオマーカー

Country Status (12)

Country Link
US (3) US11340237B2 (https=)
EP (1) EP3513197A1 (https=)
JP (4) JP7225090B2 (https=)
KR (3) KR102464380B1 (https=)
CN (2) CN117169508A (https=)
AU (2) AU2017325986B2 (https=)
CA (1) CA3037157A1 (https=)
CO (1) CO2019002607A2 (https=)
IL (2) IL265199B2 (https=)
MX (2) MX2019002918A (https=)
NZ (1) NZ792393A (https=)
WO (1) WO2018053247A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
IL265195B2 (en) 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
CA3144694A1 (en) 2019-07-25 2021-01-28 Jose A. Horcajadas Identification of viable human embryos
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20230174674A1 (en) * 2020-04-04 2023-06-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113495137A (zh) * 2021-06-29 2021-10-12 江苏省中医院 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用
CN117310059B (zh) * 2023-11-30 2024-02-02 中国人民解放军总医院 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1711828A2 (en) 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
CA2625744A1 (en) 2005-10-11 2007-04-19 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
WO2008016883A2 (en) * 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008019052A2 (en) 2006-08-03 2008-02-14 Numira Biosciences, Inc. Methods and compositions for identifying biomarkers
WO2008046511A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Crtac as a biomarker, therapeutic and diagnostic target
WO2008046509A1 (en) 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ltbp2 as a biomarker, therapeutic and diagnostic target
WO2008046528A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Npr3 as a biomarker, therapeutic and diagnostic target
WO2008046508A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
EP2087359A1 (en) 2006-10-16 2009-08-12 Bayer Schering Pharma AG Prss23 as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
ES2383235T3 (es) 2006-10-16 2012-06-19 Bayer Pharma Aktiengesellschaft CTGF como biomarcador , diana terapéutica y diagnóstica
FR2914066B1 (fr) * 2007-03-20 2009-05-22 Polyintell Sarl Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant
JP5564491B2 (ja) * 2008-04-29 2014-07-30 サイケメディクス コーポレイション 固相多分析物アッセイ法
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK2466312T3 (da) * 2009-08-12 2020-01-13 Human Metabolome Tech Inc Phosphoethanolamine som biomarkør for depression
WO2011051805A1 (en) 2009-10-27 2011-05-05 Anaxomics Biotech Sl Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
PH12012500850A1 (en) * 2009-10-30 2013-01-07 Prometheus Laboratories Inc Methods for diagnosing irritable bowel syndrome
US9494605B2 (en) * 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
EP2550533A4 (en) 2010-03-23 2014-01-08 Purdue Research Foundation EARLY RECOGNITION OF RECYCLING BREAST CANCER BY METABOLIT PROFILING
US20120040383A1 (en) 2010-08-12 2012-02-16 Wei Jia Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
JP5986440B2 (ja) 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
WO2014159637A1 (en) 2013-03-14 2014-10-02 Shire Human Genetic Therapies, Inc. Methods of treating b2-bradykinin receptor mediated angioedema
US9127024B2 (en) * 2013-03-15 2015-09-08 Intrexon Corporation Boron-containing diacylhydrazines
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
EP2884282A1 (en) * 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
EP3805756A1 (en) 2014-04-08 2021-04-14 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US20170343557A1 (en) 2014-09-22 2017-11-30 Kenneth Kun-Yu WU Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
JP6907188B2 (ja) 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
JP6570472B2 (ja) 2016-03-30 2019-09-04 株式会社マンダム 毛髪の損傷の評価方法
EA201990730A1 (ru) 2016-09-16 2019-08-30 Дайэкс Корп. Рнк-биомаркеры для наследственного ангионевротического отека
IL265195B2 (en) 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system

Similar Documents

Publication Publication Date Title
JP2023058612A5 (https=)
JP2019534446A5 (https=)
Rajska et al. Metabolomic insight into polycystic ovary syndrome—An overview
EP2502079B1 (en) New diagnostic tools for charcot-marie-tooth disease
JP2026016498A (ja) 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
Li et al. Discovery of novel lipid profiles in PCOS: do insulin and androgen oppositely regulate bioactive lipid production?
Tai et al. Development and evaluation of a reference measurement procedure for the determination of estradiol-17β in human serum using isotope-dilution liquid chromatography− tandem mass spectrometry
Feng et al. Activated NF-κB/Nrf2 and Wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria
CN111175419B (zh) 一种同时检测血液样品中多种类固醇激素的方法及试剂盒
US20100233724A1 (en) Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
JP7337701B2 (ja) インスリン及びｃ－ペプチドの定量の方法
US20120270327A1 (en) Methods and Systems for Determining the Presence or Amount of Delta 5 Steroid Compounds in a Sample
WO2010128054A1 (en) Method of diagnosing asphyxia
Blaurock et al. Metabolomics of human semen: a review of different analytical methods to unravel biomarkers for male fertility disorders
CN115963199B (zh) 一种人/动物体液中类固醇激素的定量检测方法和应用
Evangelista et al. High throughput LC-MS/MS method for steroid hormone analysis in rat liver and plasma–unraveling methodological challenges
Higashi et al. Methods for determination of fingernail steroids by LC/MS/MS and differences in their contents between right and left hands
EP4306960A1 (en) Application of composition in preparation of drug for diagnosing infantile hemangioma and/or monitoring progress and prognosis thereof, and kit and drug
Dong et al. A UHPLC-MS/MS method for profiling multifunctional steroids in human hair
Amir Hamzah et al. Advances in targeted liquid chromatography‐tandem mass spectrometry methods for endocannabinoid and N‐acylethanolamine quantification in biological matrices: A systematic review
Sun et al. Differences in first-trimester maternal metabolomic profiles in pregnancies conceived from fertility treatments
Wu et al. Analytical strategy for oxylipin annotation by combining chemical derivatization-based retention index algorithm and feature tandem mass spectrometric fragmentation as a biomarker discovery tool
ES2686542T3 (es) Medios y procedimientos para determinar una cantidad normalizada de aclaramiento de un biomarcador de enfermedad metabólica en una muestra
Li et al. Advances in steroid purification for novel techniques in carbon isotope ratio mass spectrometry of doping control
Tagawa et al. Strain differences of neurosteroid levels in mouse brain